Please assess the completion status of the following clinical trial:

Trial Title: Lopinavir/Ritonavir Monotherapy in Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV infected children ages 2 to 18 years~2. Treated with double boosted PIs during the last three months~3. Two consecutive plasma HIV-RNA levels \< 50 copies/ml at least 3 months apart~4. Willing to restart HAART with the same regimen as before enrollment, when indicated~5. Signed written informed consent~Exclusion Criteria:~1. Active AIDS-defining disease at screening~2. Pregnancy

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Children who have completed HIV-NAT 017. Children treated with other double boosted PIs such as indinavir plus lopinavir/ ritonavir are also included.

Based on this trial design, predict the completion outcome and termination type (if applicable).